| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Operating Officer | Director
1 company
Kelly Paul Edward serves as a Chief Operating Officer at RLMD. Across recent SEC filings that breaks down to 19 buys and 17 sells. Those positions are worth an estimated $1.1M at current prices.
Historically, Kelly Paul Edward's trades have earned a middling insider score of 67/100 across 4 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +49.3%.
The biggest single holding is RLMD (~$1.1M) as Chief Operating Officer. Net of sales, the recent Form 4 record there shows accumulation of 550,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2025 | RLMD Relmada Therapeutics, Inc. | Chief Operating Officer | Buy | 90,000 | $2.20 | $198,000.00 | +21.8% | +51.4% | - | |
| May 16, 2025 | RLMD Relmada Therapeutics, Inc. | Chief Operating Officer | Buy | 200,000 | $0.43 | $86,060.00 | +94.2% | +31.7% | +1396.7% | |
| Sep 9, 2024 | RLMD Relmada Therapeutics, Inc. | Director | Buy | 25,000 | $2.59 | $64,750.00 | +13.3% | -82.8% | -44.1% | |
| Apr 4, 2022 | RLMD Relmada Therapeutics, Inc. | Director | Sale+OE | 10,000 | $30.04 | $300,395.00 | -5.1% | -35.7% | -92.0% | |
| Mar 9, 2021 | RLMD Relmada Therapeutics, Inc. | Director | Sale+OE | 5,000 | $35.71 | $178,550.89 | -2.9% | - | - | |
| Feb 24, 2021 | RLMD Relmada Therapeutics, Inc. | Director | Sale+OE | 5,000 | $34.19 | $170,933.00 | -2.9% | - | - | |
| Feb 9, 2021 | RLMD Relmada Therapeutics, Inc. | Director | Sale+OE | 3,569 | $35.18 | $125,564.52 | -2.2% | - | - | |
| Feb 2, 2021 | RLMD Relmada Therapeutics, Inc. | Director | Sale+OE | 2,346 | $35.04 | $82,202.60 | -1.4% | - | - | |
| Jan 27, 2021 | RLMD Relmada Therapeutics, Inc. | Director | Sale+OE | 5,000 | $32.46 | $162,322.88 | -3.3% | - | - | |
| Jan 26, 2021 | RLMD Relmada Therapeutics, Inc. | Director | Sale+OE | 4,085 | $1,580.95 | $6,458,189.60 | -2.7% | - | - |